A deadly strain of malaria along the Thai-Cambodian border is becoming increasingly immune to treatment, threatening the global effort to end malaria, new evidence shows. Artemisinin combination therapy (ACT), whereby patients take both a fast-acting and slow-acting drug to kill the parasite, is losing its therapeutic effects as treatment is taking longer. The parasite's resistance to Artemisinin, one of two drugs in ACT therapy, is the driving factor behind the deterioration of ACT. (IRIN)
Printing articles to share with others is a breach of our terms and conditions and copyright policy. Please use the sharing options on the left side of the article. Devex Pro members may share up to 10 articles per month using the Pro share tool ( ).
About the author
Devex Editor
Thanks a lot for your interest in Devex News. To share news and views, story ideas and press releases, please email editor@devex.com. We look forward to hearing from you.
